Table 1.
The role of HDAC inhibitor in allergic diseases.
| HDACI inhibitor | Structure | Model | Clinical application | Allergic Diseases | References | |
|---|---|---|---|---|---|---|
| Trichostatin A (TSA) |
pan-inhibitors |
|
Ovalbumin-induced mouse asthma model; | Phase I clinical trials in hematologic malignancies | Asthma | (13) |
| Sodium butyrate (SoB, NaB) |
selective inhibitors |
|
Mouse model of allergic rhinitis | Phase 2 clinical trials in Shigellosis; Randomized controlled trial in inflammatory Bowel Diseases; | Allergic rhinitis | (50–53) |
| Entinostat | selective inhibitors |
|
Mouse model of oxazolone-induced contact hypersensitivity | Phase 3 clinical trials in cancer; | Contact hyper sensitivity | (54–57) |
| Valproic acid (VPA) |
selective inhibitors |
|
Asthmatic mouse model; Peripheral blood mononuclear cell | Phase 2 clinical trials in cancer | Asthma healthy donors | (58–61) |